It has been demonstrated in several studies that the elevated expression level of B2M is historically associated with poor outcome in several lymphoproliferative disorders, such as AML, myelodysplastic syndrome, and ALL (55). The gene discussed is B2M; the disease is myelodysplastic syndrome.